Rating scales in depression: limitations and pitfalls by Bech, Per
epression rating scales were introduced into
clinical psychiatry in the 1960s,with the advent of anti-
depressants such as imipramine and phenelzine.
1-3 In the
early trials, both global improvement scales and the
Hamilton Depression Rating Scale (HAM-D) were used.
As discussed by Lam et al,
1 historically the use of depres-
sion symptom scales such as the HAM-D was not a rou-
tine aspect of patient care for frontline mental health
clinicians.The present situation seems to be that we are
facing two prototypes of clinicians,“Dr Gestalt,” who
uses a global clinical impression scale,and “Dr Scales,”
who has incorporated the routine use of rating scales into
daily clinical practice.
1
When comparing Dr Gestalt with Dr Scales with respect
to limitations and pitfalls in using depression rating
scales,it seems appropriate to use the functional analysis
proposed by Emmelkamp.
2According to this proposal,
we can refer to macroanalysis and microanalysis of rat-
ing scales. Macroanalysis focuses on the diagnosis of
depression and thereby the prediction of treatment
response,while microanalysis focuses on outcome mea-
sures of treatment.At the macroanalytic level,it is appro-
priate to discuss depression rating scales such as the
HAM-D in comparison with a diagnostic system of men-
tal disorders such as the Diagnostic and Statistical Manual
of Mental Disorders, 4th ed (DSM-IV),
3 while at the
microanalytic level a direct comparison between Dr
Gestalt and Dr Scales is relevant.
Macroanalysis
Emmelkamp
2 used the polythetic algorithms of the
DSM-IV to illustrate the limitation of the clinical diag-
nosis of depression when developing treatment strategies
for the patients.According to DSM-IV,in major depres-
sion five out of nine depression symptoms have to be
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Since the introduction of antidepressants to psy-
chopharmacology in the 1960s, the Hamilton Depression
Rating Scale (HAM-D) has been the most frequently used
rating scale for depression. When used as a scale for pre-
diction of outcome with antidepressants, the HAM-D, by
its total score, has obtained limited use analogous to the
Diagnostic and Statistical Manual of Mental Disorders.
4th ed (DSM-IV) diagnosis of major depression. Most
research has been devoted to the use of the HAM-D to
discriminate between placebo and active drugs or to
show dose-response relationship in patients with major
depression. An improvement in the total HAM-D score
during a drug trial does not, however, in itself qualify
the drug as an antidepressant, because the total score is
not a sufficient statistic. The problem of statistical versus
clinical significance when analyzing placebo-controlled
trials, including dose-response relationship, is outlined,
with the recommendation to use effect size statistics.  
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totally different patients may fulfil these symptomatic
requirements, because the fixed number of five items
may refer to different items from patient to patient.
Consequently,this heterogeneity has serious limitations
for the predictive validity of the diagnosis concerning
choice of treatment.
In 1979, the Montgomery-Asberg Depression Rating
Scale (MADRS) was introduced into clinical psychiatry
because the existing depression rating scales reflected 
“ ... diagnostic features rather than being sensitive to
change ....”
4Thus,the HAM-D was considered was con-
sidered by Montgomery and Asberg to be a diagnostic
scale although Hamilton had designed it as a scale mea-
suring the severity of depressive states and not the diag-
nosis.
5
After 1980,with the introduction of the Diagnostic and
Statistical Manual of Mental Disorders,3rd ed (DSM-III)
6
the diagnosis of depression was symptom-based,but,as
illustrated by Emmelkamp,
2 the algorithm of major
depression is resistant to quantification.
Studies with the HAM-D have indicated that the HAM-
D is not a unidimensional scale,
7 suggesting that the pro-
file of factors,eg,suicidal behavior,anxiety-somatization,
sleep, and appetite or weight loss should be used in a
macroanalytic approach when developing a treatment
strategy with antidepressants.
In the study by Montgomery and Asberg,
4 the item most
sensitive to change during treatment was the sleep item;
this may be explained by the antidepressants used in the
analysis (amitriptyline,clomipramine,maprotiline,and
mianserin).One of the limitations of depression rating
scales as claimed by Montgomery and Asberg
4 was that
they are only rarely consistent in finding differences
between active drugs,even when the known mechanisms
of action are different.However,in a judgment analysis
it was found that clomipramine was superior to citalo-
pram,but only on the item of sleep and not on the spe-
cific items of depression.
8 We can thus differentiate
between sedative antidepressants such as amitriptyline,
clomipramine, and mianserin (all antihistamines) and
nonsedative antidepressants such as as citalopram or
other selective serotonin reuptake inhibitors (SSRIs).In
this context,the sleep and agitation factor on the HAM-
D might become predictive of choice of antidepressants.
However,Katz et al
9 have argued for also including fac-
tors such as somatization,hostility,and interpersonal sen-
sitivity from the Symptom Checklist (SCL-90) when
selecting the type of antidepressant.Likewise,the symp-
tom of suicidal behavior should be analyzed separately
when selecting the most appropriate treatment and care
for the patient.
Macroanalyses of rating scales are rarely performed,but
a multidimensional scale such as the HAM-D might give
the clinician better information than the DSM-IV diag-
nosis of major depression when selecting the most appro-
priate antidepressant treatment for the individual
patient.With the DSM-IV symptoms of depression it is
possible to create a profile of a patient by the score on
agitation versus retardation, suicidal behavior, sleep
problems,and weight loss versus weight gain.
The only rating scales designed specifically to measure
predictive validity of treatment by their total scores are
the Newcastle Depression Scales (Newcastle 1965
10 and
Newcastle 1971
11).With the introduction of DSM-III and
DSM-IV,the subdivision of depression into endogenous
and reactive depression was deleted,and research on the
Newcastle scales,which had been based on this concept,
became very limited.
The various guidelines on how to use the different anti-
depressants with reference to treatment-specific algo-
rithms are typically based on the safety of the drugs and
the patient-specific history of treatment resistance,rather
than on the DSM-IV diagnosis of major depression or on
a score on a depression rating scale.
12
Research on how to uncover medication history to help
with the treatment decision has been very limited.
Posternak and Zimmerman
13 have recently examined
how accurately patients can recall prior treatments with
antidepressants.The results showed that approximately
80% remembered monotherapy correctly, while only
25% recalled augmentation therapy correctly.
In the macroanalysis of the choice of treatment,it must
therefore be concluded that rating scales with a factor
profile such as the HAM-D seem to be superior to the
DSM-IV diagnosis of major depression,but the DSM-IV
depression symptoms individually can give important
information about choice of treatment.However,when
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Selected abbreviations and acronyms
CGI Clinical Global Impression Scale
DSM-IV Diagnostic and Statistical Manual of Mental
Disorders.4th ed
HAM-D Hamilton Depression Rating Scale
MADRS Montgomery-Asberg Depression Rating Scale
SSRI selective serotonin reuptake inhibitormaking decisions about individual patient-specific treat-
ments, the tolerability of the antidepressant plays an
important role,as does the history of previous outcome,
especially in regard to treatment resistance.
Microanalysis
According to Emmelkamp,
2 the microanalysis of a
depression rating scale is mainly focused on the clini-
metric analysis of outcome measurements of treatment.
This type of analysis,as discussed by Faravelli
14 is based
on certain assumptions which often involve pitfalls to
such a degree that they can lead to “evidence-biased”
rather than “evidence-based” psychiatry.The assump-
tions listed by Faravelli are:
•An illness is the sum of its symptoms;
•The symptoms are represented by the numbers associ-
ated with specific behaviors;
• Operations conducted statistically on these numbers
reflect actual changes in the clinical reality;
•The relationship among numbers is represented by sim-
ple additive effect,regardless of reciprocal interaction.
These assumptions are the focus of the dialogue between
Dr Gestalt and Dr Scales.
1 One of the aspects discussed
by Lam et al
1 is that Dr Gestalt in his treatment may
focus only on one symptom which might be misleading,
while Dr Scales has a fuller picture of the patient's cur-
rent state.From Faravelli's point of view,Dr Gestalt is a
very experienced psychiatrist,while in Lam's discussion
Dr Gestalt is as inexperienced as Dr Scales.
It is certainly a disadvantage to believe that the use of
depression rating scales is an attempt to replace experi-
enced psychiatrists by young and inexperienced clinicians
in clinical trials.In this context it is important to be aware
of the instructions for the Clinical Global Impression Scale
(CGI) by Guy.
15When using the CGI,the clinician has to
make his or her assessment on the basis of previous expe-
rience with depressed patients.It is thus with reference to
experience that the clinician should make the comparison
with all the other severely depressed patients he or she has
ever treated.In their daily routine,as stated by Hamilton,
16
experienced clinicians always perform a global rating
when assessing a depressed patient's need for hospitaliza-
tion or when deciding whether to discharge an inpatient.
The clinically most significant method for validating a
depression symptom rating scale such as the HAM-D is
to use experienced psychiatrists, both in the group of
raters making the global assessment and in the group of
raters making the rating scale assessment.This approach
was analyzed by Bech et al
17 and showed that both
groups of experienced psychiatrists were able to obtain
an adequate interobserver reliability on the global assess-
ment as well as in HAM-D ratings. An item analysis
showed that only six of the 17 HAM-D items validly
reflected the global assessment.
17These six items (HAM-
D6) are shown in Table I.The three items listed at the top
of Table I are the specific items of depression in accor-
dance with DSM-IV and the International Classification
of Diseases,10th revision (ICD-10).
18This was supported
by Hamilton in his last study,
19 in which he also demon-
strated that the item of psychic anxiety is a specific item
of depression.The remaining two items in Table I are
“guilt feelings” and “psychomotor retardation.” Guilt
feelings are the specific item of negative thoughts which,
according to Beck's cognitive model,are a central feature
of depressive states.
20 Psychomotor retardation is the
most specific observational symptom of depression,and
in the Melancholia Scale (MES),which is a depression
rating scale based on the HAM-D6, the item “psy-
chomotor retardation”has been subdivided into motor,
verbal,intellectual,and emotional retardation.
21
As discussed by Frances et al,
22 the items considered to
be most specific for a disorder such as depression might
have poor ability to discriminate this disorder from other
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Table I. Specific depression subscales derived from the HAM-D by the micro-
analytic approach.
HAM-D items HAM-D subscales
HAM-D6 Maier Core factor
(20) subscale (31) subscale (32)
Depressed mood + + +
Work and interests + + +
General somatic 
(tiredness) +
Psychic anxiety + +
Guilt feelings + + +
Psychomotor retardation + + +
Psychomotor agitation +
Suicide +
Clinimetric validity
a) global impression  
by experienced
psychiatrist + - -
b) Psychometric analysis
• Item response analysis + + -
• Factor analysis - + +disorders,and the items that are most dicriminating may
not be close to the core symptoms.The HAM-D6 items
in Table I are those that in the microanalytic sense are
specific for antidepressant activity,while the items iden-
tified at the macroanalytic level to discriminate between
treatments are,for instance,sleep,appetite,agitation,and
suicidal behavior.
Table I shows the three most frequently used subscales
for measuring antidepressant activity.The HAM-D6 has
been used in trials with fluoxetine,
23 citalopram,
24 esci-
talopram,
25 paroxetine,
26 and mirtazapine,
27 while the
Maier subscale
28 and the core factor subscale
29 have
recently been included in the duloxetine program.
30The
order of HAM-D items in Table I is listed according to
their appearance in the depressive states when having
taken into account the severity degrees of the individual
items.To be additive in Farvelli's sense, the individual
items of a rating scale must be consistently rank-ordered
according to their relation to the severity of depressive
illness.This implies that scoring of lower-prevalence items
(low appearance) presupposes scorings on higher-preva-
lence items (high appearance).Thus,a score on guilt feel-
ings or psychomotor retardation (which has low preva-
lence) has to be preceded by high scores on depressed
mood and work and interests (which have the highest
prevalence).The statistical analysis based on this crite-
rion of additivity (ie,the total score being a sufficient sta-
tistic or unidimensionality of the scale items) is referred
to as item response analysis.
26The item of psychomotor
agitation was excluded from the HAM-D6 development
by both the experienced psychiatrists
17 and by the item
response theory model
26 because of a reciprocal interac-
tion with the other items.
As indicated in Table I,the clinimetric background for
the Maier subscale is an item response analysis which
was performed in a study showing that the HAM-D6,in
contrast to the MADRS,was a unidimensional scale,and
where the Maier subscale emerged as a by-product of the
statistical analysis.
28The core factor subscale was identi-
fied by an exploratory factor analysis by Cleary,
29 but has
never been confirmed by other factor analyses.A recent
comparison between HAM-D6 and the Maier subscale
31
has shown that both scales were valid,while the CGI was
unreliable.Although the theoretical score range of the
HAM-D6 goes from 0 to 22 and that of the Maier sub-
scale from 0 to 24,the standardization of the two scales
showed identical cutoff scores.Thus,a score above 10 on
the Maier subscale indicates 18 on the HAM-D17 (mod-
erate depression) and a score above 12 indicates 25 on
the HAM-D17 (severe depression),while a score below
5 indicates 7 on the HAM-D17 (remission).As no patient
can have a maximum score on both psychomotor retar-
dation and psychomotor agitation, the Maier subscale
should be considered having a practical score range cor-
responding to the HAM-D6.
Neither in the MADRS nor in the Melancholia Scale
(MES) is the item of psychomotor agitation included.
Therefore,to develop a MADRS6 subscale to cover the
specific depression items according to Table I,only the
HAM-D6 is available.
24The psychometrically most sig-
nificant method for analyzing Faravelli's assumptions is
the use of item response theory models.
26 By use of the
nonparametric model of Mokken it has been shown that
the MADRS6 is also a unidimensional depression scale.
24
The MADRS6 includes the corresponding HAM-D6
items.
A major pitfall in a microanalysis of the HAM-D is the
use of factor analysis to test Faravelli's assumptions.A
comprehensive review by Bagby et al
7 has shown that
factor analysis as used from 1980 to 2003 in many psy-
chometric analyses of the HAM-D has identified quite
different factor scores.As discussed elsewhere,
32 the clini-
metric analysis of a rating scale should indicate to what
extent the total score is a sufficient statistic by consider-
ing both the individual items of the scale and the popu-
lation under examination.
When trying to define the antidepressant effect of a drug,
Prien and Levine
33 concluded that a greater improvement
in total HAM-D scores does not necessarily indicate anti-
depressant action (“...assume that a group treated with an
experimental drug shows significantly more improvement
than a group treated with placebo on the factors of anxi-
ety,somatization or sleep disturbances and no significant
change on other factors.These changes, by themselves,
should not qualify the drug as an antidepressant...”
33).
Another major pitfall to be considered is the use of sev-
eral depression scales in the same trial without clearly
indicating a priori which of them has been determined to
be the the primary measure of antidepressant effect.To
avoid this problem,a researcher should always use the
specific items of depression, eg, the HAM-D6 or the
MADRS6,as the primary efficacy measure.When deter-
mining clinically significant antidepressant effect,it is rec-
ommended to use standardized effect size statistics.
34
These statistics examine the reduction of rating scale
scores from baseline to end point (mean scores) for both
Clinical research
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dard deviation of the two treatments.Thus,if the baseline
score is 24 for both treatments,but the change score is 14
for the active drug while it is 10 for the placebo,and if the
pooled standard deviation is 8,then the effect size is 4/8
or 0.50.In clinical trials with antidepressants an effect size
of 0.40 or higher is considered a clinically significant
response criterion.
35This equals a 20% advantage of the
active drug over placebo by using either a global impres-
sion score of very much and much response
36 or a 50%
reduction in baseline rating scores on the HAM-D.
23
Illustrating antidepressant effect,as shown in Figure 1, is
yet another difficult area. Because both groups of
patients, ie, on active drug treatment as well as on
placebo treatment,exceed 100 subjects,a small statisti-
cally significant difference will be found.In the example
illustrated in Figure 2,it is obvious that the effect of esc-
italopram is of clinical significance (effect size >0.40) in
depressed patients after only 4 weeks.
In dose-response trials,the HAM-D6 and the MADRS6
were much more sensitive than the full versions of the
respective scales,ie,HAM-D17 and MADRS10.
23,37 Both
the HAM-D6 and the Maier subscale obtained an effect
size of approximately 0.50 for venlafaxine and 0.40 for
fluoxetine in placebo-controlled trials in patients with
major depression, while the HAM-D17 even for ven-
lafaxine,obtained an effect size of below 0.40.
38
In a comparison of most of the placebo-controlled trials
of SSRIs in patients with major depression
39 it was found
that the HAM-D17 was used more frequently than the
MADRS10.As no difference was seen between the two
scales in differentiating between active drug and placebo,
only the HAM-D17 results were considered.
39
The correct use of depression rating scales in clinical tri-
als of antidepressants is,as illustrated in Figure 2,to indi-
cate the effect size of the specific items of depression and
to accept an effect size of 0.40 or higher as being the clin-
ically significant effect.The current tradition of including
at least two depression rating scales without focusing on
the specific items of depression seems to constitute a “sci-
entific wrapping” with which the companies decorate
their antidepressants,eg,in a figure analogous to Figure
1.This industry habit of “dressing”antidepressant activ-
ity does now also include the use of the Hamilton
Anxiety Scale (HAM-A) to show the antianxiety activ-
ity of an SSRI. The 14-item version of the HAM-A
40
includes an item of depressed mood. However, when
using the HAM-A to indicate an effect on generalized
anxiety, only its specific items should be used.
41 The
HAM-A subscale with the six specific items of general-
ized anxiety is shown in Table II.
42
When evaluating the antidepressant activity of new drugs
in placebo-controlled trials,it has been customary to use
clinician-rated scales to demonstrate efficacy,ie,the bal-
ance between the specific antidepressant effect and the
safety of the drug in terms of adverse drug effects.
However, the measure of patient-rated quality of life
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Figure 1. A typical illustration from a placebo-controlled trial with a
new potential antidepressant. 
Previously presented in a poster at: 4th annual meeting of the
Scandinavian College of Neuropsychopharmacology: Elsinore,
Denmark; 2005
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Figure 2. MADRS6 and MADRS10 showing the antidepressant activity
of 20 mg escitalopram in a placebo-controlled trial in patients
with severe major depression.
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43 has implied that patient-rated depression rat-
ing scales or questionnaires should also be used in
placebo-controlled trials.In general,self-rating depres-
sion scales such as the Beck Depression Inventory (BDI)
or the Zung Depression Scale (SDS) have very rarely
been used to demonstrate the clinical effect of SSRIs.
39
Because the classical self-rating scales for depression
(BDI,SDS) cover many items,but not all specific items
of depression (Table I),it might be appropriate to include
the self-rating scale of the HAM-D as released by Bent-
Hansen et al.
44The self-rating version of the HAM-D6 is
shown in Table III.Studies are ongoing to evaluate the
sensitivity of HAM-D6 in placebo-controlled trials.
The use of a self-rating version of HAM-D has focused
on translation procedures when preparing non-English
versions of the scale.This has also implied that the pit-
falls of using nonauthorized versions of the HAM-D
have been discussed.Even in the most recently published
book on assessment scales,
1 the HAM-D17 version that is
shown is not the original English HAM-D version,
although the authors refer to Hamilton's first work with
his scale.
45 In the first version of the HAM-D,the item of
agitation was measured from 0 to 3, but in the second
version,Hamilton changed the scoring to 0-5.
5The ver-
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Table II. The specific items of generalized anxiety in HAM-A6.
Psychic anxiety (worrying)
Tension (psychic)
Fears
Difficulty in concentration
Muscular tension
Behavior during interview
Table III. The HAM-D6 Questionnaire.
(1) During the past three days
I have been in my usual good mood 0
I have felt a little more sad than usual 1
I have been clearly more sad than usual, but haven't 
felt helpless or hopeless 2
I have been so gloomy that I briefly have felt 
overpowered by hopelessness 3
I have been so low in my moods that everything 
seems dark and hopeless 4
(2) During the past three days
I have been quite satisfied with myself 0
I have been a little more self-critical than usual with 
a tendency to feel less worthy than others 1
I have been brooding over my failures in the past 2
I have been plagued with distressing guilt feelings 3
I have been convinced that my current condition 
is a punishment 4
(3) During the past three days
My daily activities have been as usual 0
I have been less interested in my usual activities 1
I have felt that I have had difficulty performing my 
daily activities, but I was still able to perform them 
with great effort 2
I have had difficulty performing even simple routine 
activities 3
I have not been able to do any of the most simple 
day-to-day activities without help 4
(4) During the past three days
I have felt neither restless nor slowed down 0
I have felt a little slowed down  1
I have felt rather slowed down or have been talking 
a little less than usual 2
I have felt clearly slowed down or subdued or have 
talked much less than usual 3
I have hardly been talking at all or felt extremely 
slowed down all the time 4
(5) During the past three days
I have been calm and relaxed 0
I have felt a little more tense or insecure than usual 1
I have been clearly more worried or tense than usual, 
but have not felt that I lost control  2
I have been so tense or worried that I have briefly 
felt close to panic 3
I have had episodes where I was overwhelmed by panic 4
(6) During the past three days
I have been as active and have had as much energy 
as usual 0
I have felt rather low in energy or physically unwell 
with some bodily pains 1
I have felt very low in energy or had bodily pains  2
In this questionnaire you will find six groups of statements. Please choose the one statement in each group that best describes
how you have been feeling over the past three days, including today, and mark it with an X in the corresponding box.213
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sion published by Lam et al
1 is an American version
which was not accepted by Hamilton himself,
46 in con-
trast to the HAM-D6 version.
47 Hamilton's criticism of
the American version included the following:“ ...A fur-
ther deficiency was that it regarded the spontaneous
mention of a symptom as indicating greater severity than
if it had been elicited by questioning.There are many
reasons why patients may not mention a symptom at an
interview. For example, they may not think it relevant
(eg,feelings of guilt),they may be embarrassed (eg,loss
of libido) or they may be too polite to mention to the
interviewer that they believe they are suffering from a
physical illness ...”
Conclusion
Since the introduction of antidepressants into psy-
chopharmacology in the 1960s,the HAM-D has been the
most frequently used rating scale for depresssion.When
used as a scale for prediction of outcome with antide-
pressants,the HAM-D by its total score has obtained lim-
ited use analogous to the DSM-IV diagnosis of major
depression.Among the individual HAM-D items or fac-
tors,sleep and agitation are associated with the sedative
antidepressants.
Most research has been devoted to the use of HAM-D
to discriminate between placebo and active drugs or to
show dose-response relationship in patients with major
depression.An improvement in the total HAM-D score
during a drug trial can,however,not in itself qualify the
drug as an antidepressant because the total score is not
a sufficient statistic.This implies that the improvement
may be found in nonspecific HAM-D factors such as
sleep,anxiety,or appetite.To overcome this major pitfall,
the specific HAM-D subscales,eg,HAM-D6 have been
discussed with reference also to the analogous subscale
from the MADRS6.
The problem of statistical versus clinical significance
when analyzing placebo-controlled trials including dose-
response relationship has been outlined, with the rec-
ommendation to use effect size statistics.
Finally,the pitfall of using unauthorized scale versions
has been discussed with reference to self-rating depres-
sion scales. ❏
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Escalas de evaluación en la depresión: 
limitaciones y obstáculos
Desde que se introdujeron los antidepresivos en la
psicofarmacología, en la década de 1960, la escala
de depresión de Hamilton (HAM-D) ha sido la
escala de evaluación para la depresión que se ha
utilizado con mayor frecuencia. Cuando se emplea
la HAM-D como escala para la predicción de la res-
puesta a los antidepresivos, por su puntuación
total, su utilización es limitada tal como ocurre con
el diagnóstico de depresión mediante el DSM-IV
(Manual Diagnóstico y Estadístico de los Trastornos
Mentales, Cuarta Edición). Se ha dedicado gran
parte de la investigación al uso de la HAM-D para
discriminar entre placebo y drogas activas o para
mostrar la relación dosis-respuesta en pacientes con
depresión mayor. Sin embargo, una mejoría en la
puntuación total de la HAM-D durante un ensayo
clínico no califica a la droga como antidepresivo, ya
que la puntuación total no es un estadístico sufi-
ciente. Se comenta el problema de la significación
estadística versus la clínica cuando se analizan los
ensayos placebo controlados incluyendo la relación
dosis-respuesta, con la recomendación de utilizar
estadísticos con efecto sobre el tamaño.  
Échelles d’évaluation dans la dépression :
pièges et limites 
Depuis l’introduction des antidépresseurs dans la
psychopharmacologie au cours des années 1960,
l’échelle d’évaluation de la dépression de Hamilton
(HAM-D) est celle la plus utilisée pour la dépression.
L’HAM-D, lorsqu’elle est utilisée comme échelle de
prévision de l’évolution avec les antidépresseurs,
atteint ses limites en raison de son score total de
même que pour le diagnostic de dépression
majeure décrit dans le DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders 4e éd). 
Une grande partie des recherches a été consacrée à
l’utilisation de la HAM-D pour différencier le pla-
cebo du médicament actif ou pour montrer les rela-
tions dose-réponse chez les patients ayant une
dépression majeure. Une amélioration du score
total de la HAM-D au cours d’une étude ne qualifie
pas, en soi, un médicament comme antidépresseur,
le score total n’étant pas une statistique suffisante.
Nous soulignons le problème de la signification sta-
tistique versus clinique en analysant des études
contrôlées contre placebo qui comprennent des
rapports dose-réponse, en recommandant l’utilisa-
tion de statistiques qui prennent en compte la taille
de l’effet.
26.Licht RW, Qvitzau S, Allerup P, Bech P. Validation of the Bech-Rafaelsen
Melancholia Scale and the Hamilton Depression Scale in patients with major
depression: is the total score a valid measure of illness severity? Acta Psychiatr
Scand. 2005;111:144-149.
27.Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using
the core items of the Hamilton Depression Scale as evidence of a pure anti-
depressive effect in the short-term treatment of major depression. Int J
Neuropsychopharmacol. 2001;4:337-345.
28.Maier W, Philipp M. Improving the assessment of severity of depressive
states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry.
1985;18:114-115.
29.Cleary PJ. Problems of internal consistency and scaling in life event
schedules. J Psychosom Res. 1981;25:309-320.
30.Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine
60 mg once daily dosing versus placebo in the acute treatment of major
depression. J Psych Research. 2002;36:383-390.
31.Ruhe H, Dekker JJ, Peen J, Holman R, de Jonghe F. Clinical use of the
Hamilton Depression Scale: is increased efficiency possible? A post hoc com-
parison of the Hamilton Depression Rating Scale, Maier and Bech subscales,
Clinical Global Impression and Symptom Checklist-90 scores. Comprehens
Psychiatry. 2005;46:417-427.
32.Bech P. Modern psychometrics in clinimetrics: Impact on clinical trials of
antidepressants. Psychother Psychosom. 2004;73:134-138. 
33.Prien RF, Levine J. Research and methodological issues for evaluating the
therapeutic effectiveness of antidepressant drugs. Psychopharmacol Bull.
1984;20:250-257.
34.Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. New York, NY:
Academic Press, 1985.
35.Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The
responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res.
2000;34:3-10. 
36.Bech P. Clinical effects of selective serotonin reuptake inhibitors. In: Dahl SG,
Gram LF, eds. Clinical Pharmacology in Psychiatry. Springer: Berlin; 1989:81-93.
37.Bech P, Andersen HF. Effective dose of escitalopram in major depressive
disorder. Nord J Pychiatry. 2005;59:406-407.
38.Entsuah R, Shaffer M, Zhang J. A critical examination of the sensitivity
of unidimensional scales derived from the Hamilton Depression Rating Scale
of antidepressant drug effects. J Psychiatr Res. 2002;36:437-448.
39.Bech P. Pharmacological treatment of depressive disorders: a review. In:
Maj, M, Sartorius N, eds. Depressive Disorders. WPA Series Evidence and Experience
in Psychiatry. 2nd ed. Chichester, UK: John Wiley & Sons; 2002:89-127.
40.Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatry. 1969;special
issue:76-79.
41.Bech P, Lunde M, Undén M. An inventory for the measurement of gen-
eralised anxiety distress symptoms, the GAD-10 Inventory. Acta Psychiatr Belg.
2005;105:111-118.42.Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement
following treatment with venlafaxine XR in patients with generalized anx-
iety disorder. Clin Psychiatry. 2001;62:888-893.
43.Bech P. Quality of Life in the Psychiatric Patient. London, UK; Mosby-Wolfe,
1998.
44.Bent-Hansen J, Lauritzen L, Clemmensen L, Lunde M, Kørner A. A defi-
nite and semi-definite questionnaire version of the Hamilton/ Melancholia
Scale. J Affect Disord. 1995;33:143-150.
45.Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry.
1960;23:56-62.
46.Hamilton M, Shapiro CM. Depression. In: Peck DF, Shapiro CM,eds.
Measuring Human Problems. Chichester, UK: John Wiley; 1990:25-65. 
47.Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for
states of anxiety, depression, mania, schizophrenia with corresponding
DSM-III syndromes. Acta Psychiatr Scand. 1986;73 (suppl 326):7-37.
Rating scales in depression - Bech Dialogues in Clinical Neuroscience - Vol 8 . No.2 . 2006
215